Clinical Report: Assessing Infection Risk in Patients with IBD Undergoing Vedolizumab Treatment
Overview
This systematic review and meta-analysis evaluated the infection risk associated with vedolizumab (VDZ) in patients with inflammatory bowel disease (IBD). The findings indicate a moderate overall infection incidence, primarily mild respiratory infections, with VDZ showing a comparable safety profile to TNF inhibitors and placebo but a higher risk compared to ustekinumab.
Background
Inflammatory bowel disease (IBD) encompasses chronic gastrointestinal inflammation, significantly impacting patient quality of life. Vedolizumab, a gut-selective monoclonal antibody, has emerged as a key treatment option for moderate-to-severe IBD. Understanding the infection risks associated with VDZ is crucial for optimizing patient management and therapeutic decision-making.
Data Highlights
Outcome
Pooled Incidence
95% CI
Overall Infection Incidence
13.08%
9.85–17.18%
Respiratory Tract Infections
4.25%
N/A
VDZ vs TNF Inhibitors (RR)
0.91
N/A
VDZ vs Placebo (RR)
1.02
N/A
VDZ vs Ustekinumab (RR)
1.63
N/A
Key Findings
The overall pooled infection incidence in VDZ-treated patients was 13.08%.
Respiratory tract infections were the most common, accounting for 4.25% of cases.
No significant difference in infection risk was found between VDZ and TNF inhibitors (RR = 0.91).
VDZ showed a higher infection risk compared to ustekinumab (RR = 1.63).
Serious systemic and rare infections were infrequent among patients treated with VDZ.
Study design and geographic region were identified as significant moderators of infection risk.
Clinical Implications
Clinicians should be aware of the moderate infection risk associated with vedolizumab, particularly the prevalence of mild respiratory infections. Comparative risk assessments between VDZ and other therapies, such as ustekinumab, are essential for informed treatment decisions.
Conclusion
Vedolizumab presents a moderate infection risk profile, primarily involving mild respiratory infections, and its safety is comparable to TNF inhibitors and placebo, though inferior to ustekinumab.
